Identifying genomic alterations in solid tumors provides critical information about tumor biology that can ultimately determine treatment selection. The Anwa Solid Tumour Profiling panel uses next-generation sequencing (NGS) technology to rapidly detect somatic mutations in solid tumors, facilitating precise detection of actionable and targetable mutations in numerous cancers, including lung, colorectal, breast, thyroid, and brain.
The profile boasts a high specificity, sensitivity, and reproducibility providing the accuracy necessary to make a confident and appropriate diagnosis and determine the prognosis. The rapid turnaround combined with the precise detection of genetic alterations and the ability to catalog the unique genetic alterations present in each tumor facilitates timely, fully-individualized treatment selection for every patient.
